Discovering the perfect biomarker for cancer progression is like finding a needle in a haystack. But with cutting-edge genomic technologies and a global perspective, we’ve found that needle. Through the use of Illumina methylation arrays, researchers analyzed breast tumor samples from Taiwanese patients and cross-referenced them with data from The Cancer Genome Atlas (TCGA) in Western countries. The EG BioMed R&D team, using this comprehensive analysis, unveiled TMEM240 as a standout candidate.
Clinical validation has shown that elevated levels of circulating methylated TMEM240 are directly linked to the presence of cancer cells, making it a powerful, non-invasive tool for tracking cancer progression.
This discovery not only enhances our understanding of cancer biology but also paves the way for more personalized and effective treatment strategies.
Published in Molecular Medicine 28: 67 (2022).